培美曲塞二钠和多西他赛单药二线治疗晚期非小细胞肺癌的临床疗效和毒副反应

Clinical efficacy of monotherapy of pemetrexed disodium and docetaxel as second-line drug in the treatment of advanced non-small cell lung cancer and its toxic and side effects

目的探讨培美曲塞二钠与多西他赛单药应用于晚期非小细胞肺癌治疗的临床疗效及毒副作用。方法选取晚期非小细胞肺癌患者97例,根据化疗药物的不同分为治疗组与对照组,治疗组患者给予培美曲塞二钠化疗,对照组患者给予多西他赛治疗,对比2组患者的临床疗效、毒副反应发生情况及生活质量。结果治疗组、对照组的总有效率分别为19.14%、16.00%(P>0.05);与对照组比较,治疗组患者贫血、白细胞减少、恶心呕吐、肝功能异常及血小板减少毒副反应的发生率均显著较低(P<0.05);2组患者社会功能、心理功能、气体功能及物质生活等方面的生活质量评分对比无显著差异(P>0.05)。结论培美曲塞二钠与多西他赛单药应用于晚期非小细胞肺癌患者的二线化疗的疗效相当,但应用培美曲塞二钠的毒副反应发生情况较低,安全性更佳。

Objective To explore clinical efficacy of monotherapy of pemetrexed disodium and docetaxel as second-line drug in the treatment of advanced non-small cell lung cancer and its toxic and side effects. Methods A total of 97 advanced non-small cell lung cancer patients in our hospital were divided into treatment group and control group according to different chemotherapeutic drugs, given pemetrexed disodium and docetaxel for the treatment, respectively. Clinical efficacy, adverse reactions and quality of life of two groups were compared. Results The total effective rate of the treatment group and control group were 19.14% , 16.00% , respectively（P 〉 0.05）. Compared with the control group, the treatment group had lower incidence rates of toxic and side effects in anemia, leukopenia, nausea and vomiting, abnormal liver function and thrombocytopenia （ P 〈 0.05 ） ; Quality of life scores in social function, psychological function, function of gas and material life in the two groups showed no significant difference （ P 〉 0.05 ）. Conclusion The efficacy of pemetrexed and docetaxel, as second-line drugs for chemotherapy, is similar for advanced non-small cell lung cancer patients, but pemetrexed is safer and has lower incidence rates of toxic and side effects.